Combination therapy

Patent metadata

Field	Value
Publication number	US-12161644-B2
Application number	US-202217684306-A
Country	US
Kind code	B2
Filing date	Mar 1, 2022
Priority date	May 23, 2017
Publication date	Dec 10, 2024
Grant date	Dec 10, 2024

First claim

What is claimed is:

1. A method for treating cancer, comprising administering:
(i) an effective amount of Compound I:

or a pharmaceutically acceptable salt thereof, and
(ii) an effective amount of a PD-1 inhibitor or PD-L1 inhibitor.

2. The method of claim 1 , wherein the PD-1 inhibitor or PD-L1 inhibitor is pidilizumab, nivolumab, pembrolizumab, atezolizumab, avelumab, BMS-936559, BGB-A317, PDR001, REGN2810, or durvalumab, or a variant or biosimilar thereof, or combinations thereof.

3. The method of claim 1 , wherein (ii) is an effective amount of a PD-1 inhibitor.

4. The method of claim 1 , wherein (ii) is an effective amount of a PD-L1 inhibitor.

5. The method of claim 3 , wherein the PD-1 inhibitor is pembrolizumab, or a variant or biosimilar thereof.

6. The method of claim 3 , wherein the PD-1 inhibitor is pembrolizumab.

7. The method of claim 1 , wherein the cancer is a hematological malignancy.

8. The method of claim 1 , wherein the cancer is a relapsed or refractory hematological malignancy.

9. The method of claim 1 , wherein the cancer is a B cell malignancy.

10. The method of claim 1 , wherein the cancer is a non-Hodgkin's lymphoma.

11. The method of claim 1 , wherein the cancer is chronic lymphocytic leukemia.

12. The method of claim 1 , wherein the cancer is follicular lymphoma.

13. The method of claim 1 , wherein the cancer is mantle cell lymphoma.

14. The method of claim 1 , wherein the cancer is extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, or splenic marginal zone lymphoma.

15. The method of claim 1 , wherein the cancer is non-small cell lung cancer.

Assignees

• Mei Pharma Inc

Inventors

• Gold Daniel P

Classifications

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title